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Shailima DV RampoguAbstract
Background: Breast cancer and diabetes mellitus type-2 are two of the major diseases, which cause death to the
women worldwide. Around 16% of the breast cancer patients also suffer from diabetes mellitus. It has been noted
that the risk of occurrence of the breast cancer is more in patients suffering from diabetes mellitus.
Methods: Owing to this, the present article deals with an objective of using the breast cancer inhibitors for the
diabetes drug target– 1ADS. Ten breast cancer inhibitors were drawn using Marvin Sketch. The docking was
performed using Molegro software (Molegro Virtual Docker, MVD).
Results: The docking wizard generated 50 poses with the highest Mol Dock score −131.649.
Conclusion: This investigation successfully evaluated the effect of breast cancer inhibitors on diabetes mellitus,
providing a new dimension in endocrine research.
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Today, cancer and diabetes are two of the major global
health risks [1,2]. There are several reports delineating
how diabetes mellitus triggers a variety of cancers [3-8].
By the year 2007, in the United Sates alone, it was noted
that about 8% of the total adult population were diabetic
and 2.5 million people were reported having breast can-
cer [9,10]. Therefore, it is important to probe the rela-
tionship between diabetes mellitus and breast cancer
The epidemiological studies have reported that the
insulin-like growth factor 1 evokes the growth of colon
tumour, suggesting the tumour growth is associated with
the levels of insulin [11-15]. Knowing the fact that dia-
betes mellitus provokes the tumour cells, it would be
ideal to design drugs that can act on both the diseases.
One of such drugs is Metformin [2], which is a known
diabetic agent acts by reducing the increased levels of in-
sulin in blood [2]. Metformin decreases hyperglycaemia
and hyperinsulinemia by increasing skeletal muscle glu-
cose uptake [2]. Increased levels of insulin-like growth
factor 1 (IGF-1) in serum/plasma are seen in prostate
cancer and pre menopausal breast cancer [16-20].Correspondence: shailima.rampogu@gmail.com
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unless otherwise stated.The association of diabetes and breast cancer is a long
debated topic. Among the cancers present today, breast
cancer is considered to be one of the causes of deaths seen
in women [21]. It was noted in 16% of the patients who
suffer from breast cancer were found to be diagnosed with
diabetes [22]. Diabetes brings about several modifications
in hormonal system [22] which could trigger the enhance-
ment of breast cancer like growth factors estrogen [22] and
other growth factors. Diabetes inhibits the AMP kinase by
decreasing the adiponectin plasma levels, which activates
certain pathways like Akt and ERK aggravating the breast
cancer risk Figure 1 [23,24].
Breast cancer is seen in association with type 2 dia-
betes in women who have reached their post meno-
pausal stage. In most of the cases it was observed that
the overweight/obese women are more likely to develop
both diseases as depicted in Figure 2.
1 ADS is the protein of interest in the present investi-
gation. The elevated levels of the enzyme aldose reduc-
tase are seen associated with diabetes nephropathy [25].
There are reports which states the action of the aldose
reductase inhibitors, which could control the diabetes
prognosis and further its complications [26,27]. This
leads to a very important notion of the use of cancer
drugs on diabetes. P.Vigneri et al. reported the use ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Pathophysiological link between Diabetes and Breast Cancer [22].
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the present article the breast cancer inhibitors are used
to bind with the aldose reductase (1ADS).
Owing to this, the aim of the present article is to use
the validated breast cancer inhibitors against the vali-
dated diabetic drug target protein via in silico analysis.Figure 2 Depiction between obesity and breast cancer.Materials and methods
Ligand preparation
The ligands used for the present study are validated
breast cancer inhibitors [29]. Ten selected ligands were
drawn using Marvin sketch, Figure 3 and subsequently
imported into the Molegro.
Figure 3 Breast cancer inhibitors.
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The protein selected for the present study was 1ADS at
the resolution 2.40 Å. The protein from the Protein Data
Bank (PDB) was downloaded and imported into Mole-
gro. The protein and the ligands were prepared assigning
“always” to the given parameters.Docking
The docking was done between the diabetes drug target
and the breast cancer inhibitors on the Molegro docking
wizard. The active sites of the protein were identified
and the site with highest area and volume was selected
for the docking, Figure 4.Figure 4 Volume of the active sites.Result
The Molegro docking wizard revealed the following
The docking wizard generated 50 poses Figure 5. The high-
est dock score, −131.649 was seen with the inhibitor 1.
Hydrogen bond interactions were seen between the follow-
ing amino acids Cys 298, Ser 210, Ser 159 and Asn 160
Figure 6.Discussion
Diabetes mellitus is one of the major metabolic disorders,
which is associated with several other complications like
nephropathy, vascular diseases and hypertension [30]. Be-
sides this, diabetes mellitus initiates tumour formation at
most of the sites [31] associated with some cancers such as
breast cancer [32] and prostate cancer [31]. Reports also in-
dicate the association of diabetes with pancreatic cancer
[33] Hence it is important to address the problem and to
evaluate the relationship between them. The present article
has successfully evaluated the use of the breast cancer
drugs on 1ADS, a diabetic drug target. This is a novel ap-
proach through which both the morbidities can be reduced.
The 10 breast cancer inhibitors considered for the
present study were proven to be effective against aroma-
tase, an enzyme seen in the breast cancer patients [21]. As
breast cancer is seen commonly in the post menopausal
diabetic women it is ideal to use a drug which could treat
both the aliments. Encouraged by this fact, the breast can-
cer drugs are used against diabetes drug target, unlike
Figure 5 Docking results.
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Figure 6 Docking result showing hydrogen bonds.
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results show a new dimension in the research for con-
trolling both the diseases, hence can reduce both the
morbidities.
Conclusion
Breast cancer and diabetes mellitus happen to be two of
the major growing health concerns in the present day.
Though not directly, diabetes mellitus is one of the
causes of breast cancer incidences. It favours the growth
of certain cancers like prostate cancer with a risk to
other organs as well [28]. The present article successfully
evaluates the role of breast cancer inhibitors on diabetes
drug target. Given the best clinical attention, the associ-
ated relationship between both the diseases can be
established, thus can cure both diseases.
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